Plain-English translation of NCT06045910 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called in people who have blood cancers (specifically B-cell lymphomas) and have already received CAR T cell therapy. is designed to work alongside or after CAR T treatment to help the immune system fight cancer cells. The study will first check if the medication is safe and find the right dose, then test whether it actually helps people with these cancers.
Some people's cancers don't fully respond to CAR T cell therapy, or the cancer comes back after initial treatment. This medication is being tested to see if it can help people whose cancers didn't respond well enough to CAR T therapy alone, or to prevent relapse.
You likely qualify if…
You likely don't qualify if…
The trial has two main phases: in the first phase, researchers will test different doses of the medication to find the safest and most effective amount; in the second phase, more people will receive the recommended dose. Participants will receive the medication by IV infusion every 2 weeks and will have regular blood tests and visits to monitor their health, response to treatment, and any side effects. The study will track how long people stay in remission and gather safety information throughout their participation.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United Kingdom